Search

Your search keyword '"Buggisch, Peter"' showing total 80 results

Search Constraints

Start Over You searched for: Author "Buggisch, Peter" Remove constraint Author: "Buggisch, Peter" Publisher elsevier b.v. Remove constraint Publisher: elsevier b.v.
80 results on '"Buggisch, Peter"'

Search Results

1. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients

2. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B

3. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure

4. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

13. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C

16. TOP-110 - Increasing functional cure rate beyond 96 weeks after discontinuation of nucleos (t)ide analogue treatment in HBeAg-negative chronic hepatitis B: follow-up of the stop-NUC trial

17. SAT-156 - Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic response

18. LBP-12 - Off-label Bulevirtide monotherapy for chronic hepatitis D virus infection in patients with decompensated liver disease

20. FRI391 - Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure

22. OS003 - Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA)

26. FRI133 - Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study

27. THU423 - Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany - analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R)

30. LBO06 - Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial

31. SAT-348-Low frequencies of lifestyle interventions and liver-specific medications in a multicentric prospective real world NAFLD cohort: The fatty liver assessment in Germany (FLAG) study

34. PS-179-Analysis of long-term persistence of HCV resistance-associated substitutions within NS, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure

37. Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.

38. Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks.

39. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B.

40. Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin.

41. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.

42. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections.

46. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

47. Escitalopram for the prevention of peginterferon alpha-2a- and ribavirin-associated depression in HCV-infected patients without prior psychiatric disease: A randomized controlled trial

48. 602 Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 (GT1) Treatment-Naïve (TN) Non-Cirrhotic (NC) Patients with HCV Viral load (VL) <6 million IU/ml (6M); A Comparative Analysis of the Phase-3 ION-3 Data to Real World Effectiveness...

Catalog

Books, media, physical & digital resources